OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma

J Hepatol. 2012 Sep;57(3):613-20. doi: 10.1016/j.jhep.2012.04.024. Epub 2012 May 19.

Abstract

Background & aims: Accumulating evidence suggests the involvement of tumor-initiating cells (T-ICs) in cancer genesis, but whether liver T-ICs contribute to HCC invasion and metastasis remains unclear.

Methods: OV6(+) T-ICs were isolated from SMMC7721 and HuH7 cell lines by magnetic sorting. Characteristics of T-ICs were assessed by in vitro and mouse xenograft assays. Expression of OV6 was determined by immunostaining in specimens from 218 HCC patients, and Kaplan-Meier survival analysis was used to determine the correlation of OV6 expression with prognosis.

Results: OV6(+) T-ICs isolated from HCC cell lines not only possess a higher capacity to form tumor spheroids in vitro, but also had a greater potential to form tumors when implanted in non-obese diabetic/severe combined immunodeficient mice, suggesting their elevated self-renewal capacity and tumorigenicity. Moreover, OV6(+) T-ICs exhibited more invasive and metastatic potentials both in vitro and in vivo. Patients with more OV6(+) tumor cells were associated with aggressive clinicopathologic features and poor prognosis. CXCR4 is expressed at higher levels in OV6(+) cells. Recombinant stromal cell-derived factor-1 (SDF-1) treatment expanded the OV6(+) HCC T-ICs population, by sustaining the stem cell property of OV6(+) cells. The SDF-1 effect was blocked by a specific CXCR4 inhibitor, AMD3100, or transfection of siRNA targeting CXCR4.

Conclusions: OV6(+) HCC cells may represent a subpopulation of T-ICs with augmented invasion and metastasis potential, which contribute to progression and metastasis of HCC. The SDF-1/CXCR4 axis also provides therapeutic targets for elimination of liver T-ICs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen
  • Animals
  • Antigens, CD / metabolism
  • Antigens, Differentiation / metabolism*
  • Antigens, Neoplasm / metabolism
  • Benzylamines
  • Carcinoma, Hepatocellular / metabolism*
  • Carcinoma, Hepatocellular / secondary*
  • Cell Adhesion Molecules / metabolism
  • Cell Line, Tumor
  • Cell Movement
  • Chemokine CXCL12 / metabolism
  • Cyclams
  • Disease Progression
  • Disease-Free Survival
  • Epithelial Cell Adhesion Molecule
  • Female
  • Gene Knockdown Techniques
  • Glycoproteins / metabolism
  • Heterocyclic Compounds / pharmacology
  • Humans
  • Kaplan-Meier Estimate
  • Liver Neoplasms / metabolism*
  • Liver Neoplasms / pathology*
  • Lung Neoplasms / metabolism*
  • Lung Neoplasms / secondary
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Invasiveness
  • Neoplastic Stem Cells / metabolism*
  • Peptides / metabolism
  • Prognosis
  • RNA, Small Interfering
  • Receptors, CXCR4 / drug effects
  • Receptors, CXCR4 / genetics
  • Receptors, CXCR4 / metabolism
  • Spheroids, Cellular

Substances

  • AC133 Antigen
  • Antigens, CD
  • Antigens, Differentiation
  • Antigens, Neoplasm
  • Benzylamines
  • CXCR4 protein, human
  • Cell Adhesion Molecules
  • Chemokine CXCL12
  • Cyclams
  • Epithelial Cell Adhesion Molecule
  • Glycoproteins
  • Heterocyclic Compounds
  • Peptides
  • RNA, Small Interfering
  • Receptors, CXCR4
  • oval cell marker OV-6
  • plerixafor